woLiver Regeneration Effect of Oncostatin M Following Hepatectomy for the Rat Cirrhotic Liver Model


Background/Aims: Liver resection represents the treatment of choice for hepatocellular carcinoma (HCC) arising in well-compensated cirrhosis. Gene expression of the multifunctional cytokine, Oncostatin M (OSM), stimulates liver regeneration and adenoviral vector expressing OSM (AdOSM) allows a persistent expression of the gene. The aim of this study is to evaluate the benefits of the preoperative injection of AdOSM to the remnant lobes to regenerate the liver. Methods: A 70% partial hepatectomy was performed in dimethylnitrosamine-administrated cirrhotic rats with a preoperative injection of AdOSM, adenoviral vector carrying β-galactosidase (AdLacZ), or phosphate-buffered saline (PBS). The morphologic, histologic, and biochemical changes in the remnant liver and survival rates were then assessed. Results: Portal injection with clamping the portal branches of the resected lobes for 5 min made it possible to effectively transduce the adenoviral vector into the remnant lobes. The ratio of the remnant liver weight/body weight (%) was 2.3 ± 0.5 in the AdOSM group, 1.1 ± 0.3 in the AdLacZ group (p < 0.001), and 1.6 ± 0.4 in the PBS group (p = 0.02). The fibrous ratio (%) was 21.3 ± 4.6 in the AdOSM group and 35.2 ± 4.5 in the AdLacZ group on day 4 after hepatectomy and fibrous status was significantly decreased in the AdOSM group (p = 0.02). Serum hyaluronic acid which is the indicator of liver fibrosis was 215 ± 141 ng/mL in the AdOSM group and 1963 ± 1225 ng/mL in the AdLacZ group (p = 0.03). Conclusions: The OSM gene therapy may increase the possibility of hepatectomy in a cirrhotic liver by improving fibrosis, hepatic function, and hepatocyte regeneration.

Share and Cite:

N. Togo, M. Ueno, K. Uchiyama, S. Ozawa and H. Yamaue, "woLiver Regeneration Effect of Oncostatin M Following Hepatectomy for the Rat Cirrhotic Liver Model," Surgical Science, Vol. 3 No. 11, 2012, pp. 530-536. doi: 10.4236/ss.2012.311105.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] K. Uchiyama, M. Ueno, T. Hama, M. Kawai, M. Tani, H. Terasawa, et al., “Recurrence of Primary Hepatocellular Carcinoma after Hepatectomy—Differences Related to Underlying Hepatitis Virus Species,” Hepatogastroenterology, Vol. 52, No. 62, 2005, pp. 591-595.
[2] K. Uchiyama, K. Mori, K. Tabuse, M. Ueno, S. Ozawa, T. Nakase, et al., “Assessment of Liver Function for Successful Hepatectomy in Patients with Hepatocellular Carcinoma with Impaired Hepatic Function,” Journal of Hepatobiliary Pancreatic Surgery, Vol. 15, No. 6, 2008, pp. 596-602 doi:10.1007/s00534-007-1326-2
[3] M. Ueno, K. Uchiyama, S. Ozawa, S. Hayami, S. Kiriyama and H. Yamaue, “A New Prediction Model of Postoperative Complications after Major Hepatectomy for Hepatocellular Carcinoma,” Digestive Surgery, Vol. 26, No. 5, 2009, pp. 392-329. doi:10.1159/000229973
[4] S. Ozawa, K. Uchiyama, M. Nakamori, K. Ueda, M. Iwahashi, H. Ueno, et al., “Combination Gene Therapy of HGF and Truncated Type II TGF-Beta Receptor for Rat Liver Cirrhosis after Partial Hepatectomy,” Surgery, Vol. 139, No. 4, 2006, pp. 563-573. doi:10.1016/j.surg.2005.10.003
[5] M. Ueno, K. Uchiyama, M. Nakamori, K. Ueda, M. Iwahashi, S. Ozawa, et al., “Adenoviral Vector Expressing Hepatocyte Growth Factor Promotes Liver Regeneration by Preoperative Injection: The Advantages of Performing Selective Injection to the Remnant Lobe,” Surgery, Vol. 141, No. 4, 2007, pp. 511-519. doi:10.1016/j.surg.2006.10.006
[6] T. Hamada, A. Sato, T. Hirano, T. Yamamoto, G. Son, M. Torii, et al., “Oncostatin M Gene Therapy Attenuates Liver Damage Induced by Dimethylnitrosamine in Rats,” American Journal of Pathology, Vol. 171, No. 3, 2007, pp. 872-881. doi:10.2353/ajpath.2007.060972
[7] K. Nakamura, H. Nonaka, H. Saito, M. Tanaka and A. Miyajima, “Hepatocyte Proliferation and Tissue Remodeling Is Impaired after Liver Injury in Oncostatin M Receptor Knockout Mice,” Hepatology, Vol. 39, No. 3, 2004, pp. 635-644. doi:10.1002/hep.20086
[8] I. Znoyko, N. Sohara, S. S. Spicer, M. Trojanowska and A. Reuben, “Expression of Oncostatin M and Its Receptors in Normal and Cirrhotic Human Liver,” Journal of Hepatology, Vol. 43, No. 5, 2005, pp. 893-900. doi:10.1016/j.jhep.2005.04.020
[9] X. J. Dong, H. Zhang, R. L. Pan, L. X. Xiang and J. Z. Shao, “Identification of Cytokines Involved in Hepatic Differentiation of mBM-MSCs under Liver-Injury Conditions,” World Journal of Gastroenterology, Vol. 16, No. 26, 2010, pp. 3267-3278. doi:10.3748/wjg.v16.i26.3267
[10] C. D. Richards, M. Shoyab, T. J. Brown and J. Gauldie, “Selective Regulation of Metalloproteinase Inhibitor (TIMP-1) by Oncostatin M in Fibroblasts in Culture,” Journal of Immunology, Vol. 150, No. 12, 1993, pp. 5596-5603.
[11] C. Kerr, C. Langdon, F. Graham, J. Gauldie, T. Hara, C. D. Richards, “Adenovirus Vector Expressing Mouse Oncostatin M Induces Acute-Phase Proteins and TIMP-1 Expression in Vivo in Mice,” Journal of Interferon & Cytokine Research, Vol. 19, no. 10, 1999, pp. 1195-1205. doi:10.1089/107999099313145
[12] F. M. Botelho, D. R. Edwards and C. D. Richards, “Oncostatin M Stimulates c-Fos to Bind a Transcriptionally Responsive AP-1 Element within the Tissue Inhibitor of Metalloproteinase-1 Promoter,” Journal of Biological Chemistry, Vol. 273, No. 9, 1998, pp. 5211-5218. doi:10.1074/jbc.273.9.5211
[13] F. Xue, T. Takahara, Y. Yata, Y. Kuwabara, E. Shinno, K. Nonome, et al., “Hepatocyte Growth Factor Gene Therapy Accelerates Regeneration in Cirrhotic Mouse Livers after Hepatectomy,” Gut, Vol. 52, No. 5, 2003, pp. 694-700. doi:10.1136/gut.52.5.694
[14] S. L. Brody and R. G. Crystal, “Adenovirus-Mediated on Vivo Gene Transfer,” Annals of the New York Academy of Sciences, Vol. 716, 1994, pp. 90-101. doi:10.1111/j.1749-6632.1994.tb21705.x
[15] D. J. Pritchard and W. H. Butler, “Apoptosis—The Mechanism of Cell Death in Dimethylnitrosamine-Induced Hepatotoxicity,” Journal of Pathology, Vol. 158, No. 3, 1989, pp. 253-260. doi:10.1002/path.1711580314
[16] L. Zender and S. Kubicka, “Molecular Pathogenesis and Targeted Therapy of Hepatocellular Carcinoma,” Onkologie, Vol. 31, 2008, pp. 550-555. doi:10.1159/000151586
[17] D. E. Cressman, L. E. Greenbaum, R. A. DeAngelis, G. Ciliberto, E. E. Furth, V. Poli, et al., “Liver Failure and Defective Hepatocyte Regeneration in Interleukin-6-Deficient Mice,” Science, Vol. 274, No. 5291, 1996, pp. 1379-1383. doi:10.1126/science.274.5291.1379
[18] A. Kamiya, T. Kinoshita, Y. Ito, T. Matsui, Y. Morikawa, K. Nakashima, et al., “Fetal Liver Development Requires a Paracrine Action of Oncostatin M through the gp130 Signal Transducer,” EMBO Journal, Vol. 18, No. 8, 1999, pp. 2127-2136. doi:10.1093/emboj/18.8.2127
[19] Y. Ito, T. Matsui, A. Kamiya, T. Kinoshita and A. Miyajima, “Retroviral Gene Transfer of Signaling Molecules into Murine Fetal Hepatocytes Defines Distinct Roles for the STAT3 and Ras Pathways during Hepatic Development,” Hepatology, Vol. 32, No. 6, 2000, pp. 1370-1376. doi:10.1053/jhep.2000.19815
[20] T. Kinoshita and A. Miyajima, “Cytokine Regulation of Liver Development,” Biochim Biophys Acta, Vol. 1592, No. 3, 2002, pp. 303-312. doi:10.1016/S0167-4889(02)00323-3
[21] T. Yamashita, M. Honda, K. Nio, Y. Nakamoto, T. Yamashita, H. Takamura, et al., “Oncostatin m Renders Epithelial Cell Adhesion Molecule-Positive Liver Cancer Stem Cells Sensitive to 5-Fluorouracil by Inducing Hepatocytic Differentiation,” Cancer Research, Vol. 70, No. 11, 2010, pp. 4687-4697. doi:10.1158/0008-5472.CAN-09-4210

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.